Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,053 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial.
Roth P, Gorlia T, Reijneveld JC, de Vos F, Idbaih A, Frenel JS, Le Rhun E, Sepulveda JM, Perry J, Masucci GL, Freres P, Hirte H, Seidel C, Walenkamp A, Lukacova S, Meijnders P, Blais A, Ducray F, Verschaeve V, Nicholas G, Balana C, Bota DA, Preusser M, Nuyens S, Dhermain F, van den Bent M, O'Callaghan CJ, Vanlancker M, Mason W, Weller M; EORTC Brain Tumor Group and the Canadian Cancer Trials Group. Roth P, et al. Among authors: mason w. Neuro Oncol. 2024 Mar 19:noae053. doi: 10.1093/neuonc/noae053. Online ahead of print. Neuro Oncol. 2024. PMID: 38502052
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Mirimanoff RO, et al. Among authors: mason w. J Clin Oncol. 2006 Jun 1;24(16):2563-9. doi: 10.1200/JCO.2005.04.5963. J Clin Oncol. 2006. PMID: 16735709 Clinical Trial.
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD; BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium. Reardon DA, et al. Among authors: mason wp. Neuro Oncol. 2015 Mar;17(3):430-9. doi: 10.1093/neuonc/nou160. Epub 2014 Aug 19. Neuro Oncol. 2015. PMID: 25140039 Free PMC article. Clinical Trial.
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T. Wick W, et al. Among authors: mason w. Neuro Oncol. 2016 Oct;18(10):1434-41. doi: 10.1093/neuonc/now091. Epub 2016 Aug 11. Neuro Oncol. 2016. PMID: 27515827 Free PMC article. Clinical Trial.
Long-term outcomes for adult craniopharyngioma following radiation therapy.
Masson-Cote L, Masucci GL, Atenafu EG, Millar BA, Cusimano M, Croul S, Mason W, Laperriere NJ, Sahgal A. Masson-Cote L, et al. Among authors: mason w. Acta Oncol. 2013 Jan;52(1):153-8. doi: 10.3109/0284186X.2012.685525. Epub 2012 May 8. Acta Oncol. 2013. PMID: 22568405
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A; European Organisation for Research and Treatment of Cancer Brain Tumour Group; EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group. Taphoorn MJ, et al. Among authors: mason w. Lancet Oncol. 2005 Dec;6(12):937-44. doi: 10.1016/S1470-2045(05)70432-0. Lancet Oncol. 2005. PMID: 16321761 Clinical Trial.
1,053 results